About Pionyr Immuntherapeutics
Pionyr Immuntherapeutics is a company based in San Francisco (United States) founded in 2015 was acquired by Ikena Oncology in August 2023.. Pionyr Immuntherapeutics has raised $352 million across 4 funding rounds from investors including Gilead, Ikena Oncology and Orbimed. Pionyr Immuntherapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter San Francisco, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$352 M (USD)
in 4 rounds
-
Latest Funding Round
$275 M (USD), Series C
Jun 23, 2020
-
Investors
Gilead
& 8 more
-
Employee Count
Employee Count
-
Acquired by
Ikena Oncology
(Aug 07, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Pionyr Immuntherapeutics
Pionyr Immuntherapeutics has successfully raised a total of $352M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $275 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series C — $275.0M
-
First Round
First Round
(04 Jan 2017)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2020 | Amount | Series C - Pionyr Immuntherapeutics | Valuation | Gilead |
|
| Mar, 2018 | Amount | Series B - Pionyr Immuntherapeutics | Valuation |
investors |
|
| Dec, 2017 | Amount | Series B - Pionyr Immuntherapeutics | Valuation | New Enterprise Associates |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Pionyr Immuntherapeutics
Pionyr Immuntherapeutics has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Gilead, Ikena Oncology and Orbimed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech funding, drug development support, and investment in life sciences.
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Venture capital fund focused on early-stage healthcare startups
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Pionyr Immuntherapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Pionyr Immuntherapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Pionyr Immuntherapeutics Comparisons
Competitors of Pionyr Immuntherapeutics
Pionyr Immuntherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Pionyr Immuntherapeutics
Frequently Asked Questions about Pionyr Immuntherapeutics
When was Pionyr Immuntherapeutics founded?
Pionyr Immuntherapeutics was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Where is Pionyr Immuntherapeutics located?
Pionyr Immuntherapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is Pionyr Immuntherapeutics a funded company?
Pionyr Immuntherapeutics is a funded company, having raised a total of $352M across 4 funding rounds to date. The company's 1st funding round was a Series B of $62M, raised on Jan 04, 2017.
What does Pionyr Immuntherapeutics do?
Pionyr Immuntherapeutics was founded in 2015 in San Francisco, United States, focusing on the biotechnology sector. Cancer immunotherapies are developed by the company to target the tumor microenvironment and enhance antitumor immunity through its Myeloid Tuning approach. Technology has been licensed from UC San Francisco and the University of Toronto, with collaboration established with Adimab. Lead programs remain in the discovery stage.
Who are the top competitors of Pionyr Immuntherapeutics?
Pionyr Immuntherapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Who are Pionyr Immuntherapeutics's investors?
Pionyr Immuntherapeutics has 9 investors. Key investors include Gilead, Ikena Oncology, Orbimed, Sofinnova, and SV Health Investors.